Transverse Myelitis Trial, Recruiting (NCT06780709)

Transverse Myelitis Trial, Recruiting NCT06780709 Sponsor: Icahn School of Medicine at Mount Sinai Condition: Transverse Myelitis

Printed from Voxsanity (voxsanity.com.au) — NCT06780709 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Transverse Myelitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older who have been diagnosed with a condition called NMOSD (Neuromyelitis Optica Spectrum Disorder) using specific 2015 medical guidelines
People at any level of disability are welcome — there are no restrictions based on how much the condition affects your daily functioning
People currently taking any type of medication or treatment for their condition are eligible to apply

Who may not be able to join:

Anyone under the age of 18
Anyone who is unable to freely and willingly agree to take part in the study on their own
Anyone who is unable to complete the study's tests or assessments, or who is already taking part in another research trial or wellness programme at the same time
Anyone who has had a relapse (a flare-up of symptoms) within the 30 days before being enrolled into the study, or anyone whose doctor has advised them not to do physical activity
Anyone who starts taking stimulant medications or a specific drug called dalfampridine after signing up but before being officially assigned to a study group

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 29 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sammita Satyanarayan, MD, Icahn School of Medicine at Mount Sinai

Phone: 212-241-3841

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06780709

Sponsor: Icahn School of Medicine at Mount Sinai

Phase: Not Applicable

Status: Recruiting

Condition: Transverse Myelitis

Trial contact: 212-241-3841

More information: https://clinicaltrials.gov/study/NCT06780709

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older who have been diagnosed with a condition called NMOSD (Neuromyelitis Optica Spectrum Disorder) using specific 2015 medical guidelines
People at any level of disability are welcome — there are no restrictions based on how much the condition affects your daily functioning
People currently taking any type of medication or treatment for their condition are eligible to apply

Who may not be able to join:

Anyone under the age of 18
Anyone who is unable to freely and willingly agree to take part in the study on their own
Anyone who is unable to complete the study's tests or assessments, or who is already taking part in another research trial or wellness programme at the same time
Anyone who has had a relapse (a flare-up of symptoms) within the 30 days before being enrolled into the study, or anyone whose doctor has advised them not to do physical activity
Anyone who starts taking stimulant medications or a specific drug called dalfampridine after signing up but before being officially assigned to a study group

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 29 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Icahn School of Medicine at Mount Sinai

Registry

ClinicalTrials.gov

Start date

21 January 2025

Est. completion

1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Multiple Sclerosis Quality of Life (MSQOL-54) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov